The Michael J. Fox Foundation will award one-year to 18-month grants for studies that explore the role of astrocytes in Parkinson’s disease (PD) pathology and the potential for astrocyte-focused therapeutics. The goals of this funding program are to further understanding of astrocyte biology in Parkinson’s and to rationalize the pursuit of astrocyte-specific targets and/or pathways for the treatment of the disease.
Preference will be given to applications that focus on or include the following:
- Role of astrocytes in initiating and/or propagating Parkinson’s disease pathology, including alpha-synuclein spread, dopaminergic neuron death, inflammation and senescence
- Consequences of dysfunction and/or mutations of common PD targets, including alpha-synuclein, LRRK2, GBA, PRKN and PINK1
- Manipulation of astrocyte activity and/or astrocyte-specific pathways to assess the potential of targeted astrocyte therapies on disease biology and/or symptoms
- Parkinson’s disease models with high construct validity to human PD, including patient-derived material (such as iPSCs or cerebral organoids) and/or well characterized animal models and primary cells; Examination of human brain samples to answer specific hypotheses is also acceptable
- Targets, pathways and mechanisms with reasonable links to PD
Watch a previously recorded webinar on our Foundation's funding strategy and opportunities, and the application and review processes